Adult and paediatric patients with pathogenic variants in the gene encoding succinate
dehydrogenase (SDH) subunit B (SDHB) often have locally aggressive, recurrent or …

Lutathera® is the first EMA-and FDA-approved radiopharmaceutical for radioligand therapy
(RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive …

Cardiac tumors may be primary (either benign or malignant) or secondary (malignant) and
are first detected by echocardiography in most cases. The cardiologist often challenges their …

Paragangliomas can metastasize, posing potential challenges both in symptomatic
management and disease control. Systemic targeted radiotherapies using 131I-MIBG and …

Purpose The current guidelines state that the functional imaging choice in the evaluation of
metastatic pheochromocytoma and paraganglioma (PPGL) is 68 Ga-DOTATATE PET/CT. 18 …

Simple Summary Pheochromocytomas and paragangliomas are rare neural-crest-derived
tumors with variable prognosis. In an era of tailored treatment strategies, medical imaging …

Whereas benign pheochromocytomas and paragangliomas are often successfully cured by
surgical resection, treatment of metastatic disease can be challenging in terms of both …

Although pediatric pheochromocytomas and paragangliomas (PPGLs) are rare, they have
important differences compared to those in adults. Unfortunately, without timely diagnosis …

Somatostatin receptor (SSTR) imaging has brought about impactful changes in clinical
management of neuroendocrine tumors (NETs), including pheochromocytoma and …

Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-producing
neuroendocrine tumors derived from chromaffin cells. 1–3 Pheochromocytomas are derived …